Comparison of invasive and noninvasive measurement of plasma disappearance rate of indocyanine green in patients undergoing liver transplantation: A prospective investigator‐blinded study

Peter Faybik, Claus‐Georg Krenn, Amir Baker, Daniel Lahner, Gabriela Berlakovich, Heinz Steltzer, Hubert Hetz – 23 July 2004 – Plasma disappearance rate of indocyanine green (PDRICG) has been proposed for assessment of liver function in liver transplants donors and recipients, in patients with chronic liver failure, and as a prognostic factor in critically ill patients. The assessment of PDRICG using a newly developed noninvasive digital pulse densitometry method was simultaneously compared to invasive aortic fiber‐optic method in patients undergoing orthotopic liver transplantation (OLT).

Predictors of length of stay for pediatric liver transplant recipients

John C. Bucuvalas, Lan Zeng, Ravinder Anand, The Studies of Pediatric Liver Transplantation (SPLIT) Research Group – 23 July 2004 – The resources that are directed towards the care of liver transplant recipients are substantial. Approximately 100 million dollars are spent on the hospitalization of the 400–500 children in the United States who undergo liver transplantation each year.

Risk of diabetes in HIV infected veterans pre‐ and post‐HAART and the role of HCV coinfection

Adeel A. Butt, Shawn L. Fultz, C. Kent Kwoh, David Kelley, Melissa Skanderson, Amy C. Justice – 30 June 2004 – We examined the association of hepatitis C virus (HCV) infection with diabetes in veterans infected with human immunodeficiency virus (HIV) before and after the institution of highly active antiretroviral therapy (HAART). The role of age, race, liver disease, alcohol, and drug diagnoses upon the risk of diabetes was also determined. Male veterans with HIV who entered care between 1992 and 2001 were identified from the Veterans Affairs (VA) administrative database.

“Hope” for the liver? Mechanistic insight into the role of the renin‐angiotensin system in hepatic fibrosis

Gavin E. Arteel – 30 June 2004 – Angiotensin II (AngII) is a pro‐oxidant and fibrogenic cytokine. We investigated the role of NADPH oxidase in AngII‐induced effects in hepatic stellate cells (HSCs), a fibrogenic cell type. Human HSCs express mRNAs of key components of nonphagocytic NADPH oxidase. AngII phosphorylated p47phox, a regulatory subunit of NADPH oxidase, and induced reactive oxygen species formation via NADPH oxidase activity. AngII phosphorylated AKT and MAPKs and increased AP‐1 DNA binding in a redox‐sensitive manner.

Mechanism of action of the antifibrogenic compound gliotoxin in rat liver cells

James G. Orr, Val Leel, Gary A. Cameron, Carylyn J. Marek, Emma L. Haughton, Lucy J. Elrick, Julie E. Trim, Gabrielle M. Hawksworth, Andrew P. Halestrap, Matthew C. Wright – 30 June 2004 – Gliotoxin has been shown to promote a reversal of liver fibrosis in an animal model of the disease although its mechanism of action in the liver is poorly defined. The effects of gliotoxin on activated hepatic stellate cells (HSCs) and hepatocytes have therefore been examined.

A phase II dose‐escalating trial of clevudine in patients with chronic hepatitis B

Patrick Marcellin, Herve Mommeja‐Marin, Stephen L. Sacks, George K. K. Lau, Daniel Sereni, Jean‐Pierre Bronowicki, Brian Conway, Christian Trepo, M. Robert Blum, Byung Chul Yoo, Elsa Mondou, Jeff Sorbel, Andrea Snow, Franck Rousseau, Hyo‐Suk Lee – 30 June 2004 – Current therapies available for the treatment of chronic hepatitis B are limited in their ability to result in a cure. Clevudine is a new pyrimidine analog with potent anti‐hepatitis B virus (HBV) activity in vitro. A multicenter dose‐escalation study evaluated clevudine at 10, 50, 100, and 200 mg once daily for 28 days.

Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis

Michael Schepke, Gerhard Kleber, Dieter Nürnberg, Jörg Willert, Lydia Koch, Wilfried Veltzke‐Schlieker, Claus Hellerbrand, Johannes Kuth, Stefan Schanz, Stefan Kahl, Wolfgang E. Fleig, Tilman Sauerbruch – 30 June 2004 – In this randomized controlled multicenter trial, we compared endoscopic variceal banding ligation (VBL) with propranolol (PPL) for primary prophylaxis of variceal bleeding. One hundred fifty‐two cirrhotic patients with 2 or more esophageal varices (diameter >5 mm) without prior bleeding were randomized to VBL (n = 75) or PPL (n = 77).

Subscribe to